1-20 of 20
Srdan Verstovsek
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

5-azacytidine(5- AC), all-trans retinoic acid (ATRA), and valproic acid (VPA) in patients with acute myelogenous leukemia (AML): Molecular and clinical implications

Andres Soriano, Hui Yang, Srdan Verstovsek, William Wierda, Charles Koller, Zeev Estrov, Souzanne Ouzounian, Hagop Kantarjian, Jean Pierre Issa, Guillermo Garcia-Manero
Journal: Clinical Cancer Research
Clin Cancer Res (2006) 12 (19_Supplement): B48.
Published: 15 August 2014
View article titled, 5-azacytidine(5- AC), all-trans retinoic acid (ATRA), and valproic acid (VPA) in patients with acute myelogenous leukemia (AML): Molecular and clinical implications
Journal Articles

Mutation profile of JAK2 gene in patients with chronic myeloproliferative neoplasias

Wanlong Ma, Hagop Kantarjian, Xi Zhang, Chen-Hsiung Yeh, Zhong Zhang, Srdan Verstovsek, Maher Albitar
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (19_Supplement): B12.
Published: 15 August 2014
View article titled, Mutation profile of JAK2 gene in patients with chronic myeloproliferative neoplasias
Journal Articles

Molecular Pathways: JAK/STAT Pathway: Mutations, Inhibitors, and Resistance

Alfonso Quintás-Cardama, Srdan Verstovsek
Journal: Clinical Cancer Research
Clin Cancer Res (2013) 19 (8): 1933–1940.
https://doi.org/10.1158/1078-0432.CCR-12-0284
Published: 15 April 2013
View article titled, Molecular Pathways: JAK/STAT Pathway: Mutations, Inhibitors, and Resistance
Open the PDF for Molecular Pathways: JAK/STAT Pathway: Mutations, Inhibitors, and Resistance in another window
Journal Articles

The Role of JAK Pathway Dysregulation in the Pathogenesis and Treatment of Acute Myeloid Leukemia

Hun Ju Lee, Naval Daver, Hagop M. Kantarjian, Srdan Verstovsek, Farhad Ravandi
Journal: Clinical Cancer Research
Clin Cancer Res (2013) 19 (2): 327–335.
https://doi.org/10.1158/1078-0432.CCR-12-2087
Published: 16 January 2013
View article titled, The Role of JAK Pathway Dysregulation in the Pathogenesis and Treatment of Acute Myeloid Leukemia
Open the PDF for The Role of JAK Pathway Dysregulation in the Pathogenesis and Treatment of Acute Myeloid Leukemia in another window
Journal Articles

Heat Shock Protein 90 Inhibitor Is Synergistic with JAK2 Inhibitor and Overcomes Resistance to JAK2-TKI in Human Myeloproliferative Neoplasm Cells

Warren Fiskus, Srdan Verstovsek, Taghi Manshouri, Rekha Rao, Ramesh Balusu, Sreedhar Venkannagari, Nalabothula Narasimha Rao, Kyungsoo Ha, Jacqueline E. Smith, Stacey L. Hembruff, Sunil Abhyankar, Joseph McGuirk, Kapil N. Bhalla
Journal: Clinical Cancer Research
Clin Cancer Res (2011) 17 (23): 7347–7358.
https://doi.org/10.1158/1078-0432.CCR-11-1541
Published: 30 November 2011
View article titled, Heat Shock Protein 90 Inhibitor Is Synergistic with JAK2 Inhibitor and Overcomes Resistance to JAK2-TKI in Human Myeloproliferative Neoplasm Cells
Open the PDF for Heat Shock Protein 90 Inhibitor Is Synergistic with JAK2 Inhibitor and Overcomes Resistance to JAK2-TKI in Human Myeloproliferative Neoplasm Cells in another window
Includes: Supplementary data
Journal Articles

Therapeutic Potential of Janus-activated Kinase-2 Inhibitors for the Management of Myelofibrosis

Srdan Verstovsek
Journal: Clinical Cancer Research
Clin Cancer Res (2010) 16 (7): 1988–1996.
https://doi.org/10.1158/1078-0432.CCR-09-2836
Published: 31 March 2010
View article titled, Therapeutic Potential of Janus-activated Kinase-2 Inhibitors for the Management of Myelofibrosis
Open the PDF for Therapeutic Potential of Janus-activated Kinase-2 Inhibitors for the Management of Myelofibrosis in another window
Journal Articles

A Phase I Clinical Trial of Darinaparsin in Patients with Refractory Solid Tumors

Apostolia Maria Tsimberidou, Luis H. Camacho, Srdan Verstovsek, Chaan Ng, David S. Hong, Cynthia K. Uehara, Catalina Gutierrez, Shawn Daring, Jan Stevens, Philip B. Komarnitsky, Brian Schwartz, Razelle Kurzrock
Journal: Clinical Cancer Research
Clin Cancer Res (2009) 15 (14): 4769–4776.
https://doi.org/10.1158/1078-0432.CCR-08-2984
Published: 15 July 2009
View article titled, A Phase I Clinical Trial of Darinaparsin in Patients with Refractory Solid Tumors
Open the PDF for A Phase I Clinical Trial of Darinaparsin in Patients with Refractory Solid Tumors in another window
Journal Articles

Alemtuzumab Therapy for Hypereosinophilic Syndrome and Chronic Eosinophilic Leukemia

Srdan Verstovsek, Ayalew Tefferi, Hagop Kantarjian, Taghi Manshouri, Raja Luthra, Animesh Pardanani, Alfonso Quintás-Cardama, Farhad Ravandi, Pat Ault, Carlos Bueso-Ramos, Jorge E. Cortes
Journal: Clinical Cancer Research
Clin Cancer Res (2009) 15 (1): 368–373.
https://doi.org/10.1158/1078-0432.CCR-08-1302
Published: 31 December 2008
View article titled, Alemtuzumab Therapy for Hypereosinophilic Syndrome and Chronic Eosinophilic Leukemia
Open the PDF for Alemtuzumab Therapy for Hypereosinophilic Syndrome and Chronic Eosinophilic Leukemia in another window
Journal Articles

Phase II Study of Dasatinib in Philadelphia Chromosome–Negative Acute and Chronic Myeloid Diseases, Including Systemic Mastocytosis

Srdan Verstovsek, Ayalew Tefferi, Jorge Cortes, Susan O'Brien, Guillermo Garcia-Manero, Animesh Pardanani, Cem Akin, Stefan Faderl, Taghi Manshouri, Deborah Thomas, Hagop Kantarjian
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (12): 3906–3915.
https://doi.org/10.1158/1078-0432.CCR-08-0366
Published: 16 June 2008
View article titled, Phase II Study of Dasatinib in Philadelphia Chromosome–Negative Acute and Chronic Myeloid Diseases, Including Systemic Mastocytosis
Open the PDF for Phase II Study of Dasatinib in Philadelphia Chromosome–Negative Acute and Chronic Myeloid Diseases, Including Systemic Mastocytosis in another window
Journal Articles

WP1066, a Novel JAK2 Inhibitor, Suppresses Proliferation and Induces Apoptosis in Erythroid Human Cells Carrying the JAK2 V617F Mutation

Srdan Verstovsek, Taghi Manshouri, Alfonso Quintás-Cardama, David Harris, Jorge Cortes, Francis J. Giles, Hagop Kantarjian, Waldemar Priebe, Zeev Estrov
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (3): 788–796.
https://doi.org/10.1158/1078-0432.CCR-07-0524
Published: 01 February 2008
View article titled, WP1066, a Novel JAK2 Inhibitor, Suppresses Proliferation and Induces Apoptosis in Erythroid Human Cells Carrying the JAK2 V617F Mutation
Open the PDF for WP1066, a Novel JAK2 Inhibitor, Suppresses Proliferation and Induces Apoptosis in Erythroid Human Cells Carrying the JAK2 V617F Mutation in another window
Journal Articles

Phase I Study of Alternate-Week Administration of Tipifarnib in Patients with Myelodysplastic Syndrome

Razelle Kurzrock, Hagop M. Kantarjian, Michelle A. Blascovich, Cindy Bucher, Srdan Verstovsek, John J. Wright, Susan R. Pilat, Jorge E. Cortes, Elihu H. Estey, Francis J. Giles, Miloslav Beran, Said M. Sebti
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (2): 509–514.
https://doi.org/10.1158/1078-0432.CCR-07-1532
Published: 25 January 2008
View article titled, Phase I Study of Alternate-Week Administration of Tipifarnib in Patients with Myelodysplastic Syndrome
Open the PDF for Phase I Study of Alternate-Week Administration of Tipifarnib in Patients with Myelodysplastic Syndrome in another window
Journal Articles

Phase I/II Study of the Mammalian Target of Rapamycin Inhibitor Everolimus (RAD001) in Patients with Relapsed or Refractory Hematologic Malignancies

Karen W.L. Yee, Zhihong Zeng, Marina Konopleva, Srdan Verstovsek, Farhad Ravandi, Alessandra Ferrajoli, Deborah Thomas, William Wierda, Efrosyni Apostolidou, Maher Albitar, Susan O'Brien, Michael Andreeff, Francis J. Giles
Journal: Clinical Cancer Research
Clin Cancer Res (2006) 12 (17): 5165–5173.
https://doi.org/10.1158/1078-0432.CCR-06-0764
Published: 01 September 2006
View article titled, Phase I/II Study of the Mammalian Target of Rapamycin Inhibitor Everolimus (RAD001) in Patients with Relapsed or Refractory Hematologic Malignancies
Open the PDF for Phase I/II Study of the Mammalian Target of Rapamycin Inhibitor Everolimus (RAD001) in Patients with Relapsed or Refractory Hematologic Malignancies in another window
Journal Articles

Phase I Study of Cloretazine (VNP40101M), a Novel Sulfonylhydrazine Alkylating Agent, Combined with Cytarabine in Patients with Refractory Leukemia

Francis Giles, Srdan Verstovsek, Deborah Thomas, Stanton Gerson, Jorge Cortes, Stefan Faderl, Alessandra Ferrajoli, Farhad Ravandi, Steven Kornblau, Guillermo Garcia-Manero, Elias Jabbour, Susan O'Brien, Verena Karsten, Ann Cahill, Karen Yee, Maher Albitar, Mario Sznol, Hagop Kantarjian
Journal: Clinical Cancer Research
Clin Cancer Res (2005) 11 (21): 7817–7824.
https://doi.org/10.1158/1078-0432.CCR-05-1070
Published: 08 November 2005
View article titled, Phase I Study of Cloretazine (VNP40101M), a Novel Sulfonylhydrazine Alkylating Agent, Combined with Cytarabine in Patients with Refractory Leukemia
Open the PDF for Phase I Study of Cloretazine (VNP40101M), a Novel Sulfonylhydrazine Alkylating Agent, Combined with Cytarabine in Patients with Refractory Leukemia in another window
Journal Articles

Phase 1 Study of ABT-751, a Novel Microtubule Inhibitor, in Patients with Refractory Hematologic Malignancies

Karen W.L. Yee, Anne Hagey, Srdan Verstovsek, Jorge Cortes, Guillermo Garcia-Manero, Susan M. O'Brien, Stefan Faderl, Deborah Thomas, William Wierda, Steven Kornblau, Alessandra Ferrajoli, Maher Albitar, Evelyn McKeegan, David R. Grimm, Toby Mueller, Rhonda R. Holley-Shanks, Leonardo Sahelijo, Gary B. Gordon, Hagop M. Kantarjian, Francis J. Giles
Journal: Clinical Cancer Research
Clin Cancer Res (2005) 11 (18): 6615–6624.
https://doi.org/10.1158/1078-0432.CCR-05-0650
Published: 15 September 2005
View article titled, Phase 1 Study of ABT-751, a Novel Microtubule Inhibitor, in Patients with Refractory Hematologic Malignancies
Open the PDF for Phase 1 Study of ABT-751, a Novel Microtubule Inhibitor, in Patients with Refractory Hematologic Malignancies in another window
Journal Articles

AMN107, a Novel Aminopyrimidine Inhibitor of Bcr-Abl, Has In vitro Activity against Imatinib-Resistant Chronic Myeloid Leukemia

Mirna Golemovic, Srdan Verstovsek, Francis Giles, Jorge Cortes, Taghi Manshouri, Paul W. Manley, Jürgen Mestan, Margaret Dugan, Leila Alland, James D. Griffin, Ralph B. Arlinghaus, Tong Sun, Hagop Kantarjian, Miloslav Beran
Journal: Clinical Cancer Research
Clin Cancer Res (2005) 11 (13): 4941–4947.
https://doi.org/10.1158/1078-0432.CCR-04-2601
Published: 06 July 2005
View article titled, AMN107, a Novel Aminopyrimidine Inhibitor of Bcr-Abl, Has <em>In vitro</em> Activity against Imatinib-Resistant Chronic Myeloid Leukemia
Open the PDF for AMN107, a Novel Aminopyrimidine Inhibitor of Bcr-Abl, Has <em>In vitro</em> Activity against Imatinib-Resistant Chronic Myeloid Leukemia in another window
Journal Articles

Molecular Responses in Patients with Chronic Myelogenous Leukemia in Chronic Phase Treated with Imatinib Mesylate

Jorge Cortes, Moshe Talpaz, Susan O'Brien, Dan Jones, Rajyalakshmi Luthra, Jenny Shan, Francis Giles, Stefan Faderl, Srdan Verstovsek, Guillermo Garcia-Manero, Mary B. Rios, Hagop Kantarjian
Journal: Clinical Cancer Research
Clin Cancer Res (2005) 11 (9): 3425–3432.
https://doi.org/10.1158/1078-0432.CCR-04-2139
Published: 02 May 2005
View article titled, Molecular Responses in Patients with Chronic Myelogenous Leukemia in Chronic Phase Treated with Imatinib Mesylate
Open the PDF for Molecular Responses in Patients with Chronic Myelogenous Leukemia in Chronic Phase Treated with Imatinib Mesylate in another window
Journal Articles

A Phase I and Pharmacokinetic Study of VNP40101M, a Novel Sulfonylhydrazine Alkylating Agent, in Patients with Refractory Leukemia

Francis Giles, Deborah Thomas, Guillermo Garcia-Manero, Stefan Faderl, Jorge Cortes, Srdan Verstovsek, Alessandra Ferrajoli, Sima Jeha, Miloslav Beran, Charles Koller, Michael Andreeff, Ann Cahill, Caroline Clairmont, Mario Sznol, Hagop Kantarjian
Journal: Clinical Cancer Research
Clin Cancer Res (2004) 10 (9): 2908–2917.
https://doi.org/10.1158/1078-0432.CCR-03-0738
Published: 06 May 2004
View article titled, A Phase I and Pharmacokinetic Study of VNP40101M, a Novel Sulfonylhydrazine Alkylating Agent, in Patients with Refractory Leukemia
Open the PDF for A Phase I and Pharmacokinetic Study of VNP40101M, a Novel Sulfonylhydrazine Alkylating Agent, in Patients with Refractory Leukemia in another window
Journal Articles

Survival Advantage with Imatinib Mesylate Therapy in Chronic-Phase Chronic Myelogenous Leukemia (CML-CP) after IFN-α Failure and in Late CML-CP, Comparison with Historical Controls

Hagop Kantarjian, Susan O’Brien, Jorge Cortes, Francis Giles, Jianqin Shan, Mary Beth Rios, Stefan Faderl, Srdan Verstovsek, Guillermo Garcia-Manero, William Wierda, Steven Kornblau, Alessandra Ferrajoli, Michael Keating, Moshe Talpaz
Journal: Clinical Cancer Research
Clin Cancer Res (2004) 10 (1): 68–75.
https://doi.org/10.1158/1078-0432.CCR-1035-3
Published: 20 January 2004
View article titled, Survival Advantage with Imatinib Mesylate Therapy in Chronic-Phase Chronic Myelogenous Leukemia (CML-CP) after IFN-α Failure and in Late CML-CP, Comparison with Historical Controls
Open the PDF for Survival Advantage with Imatinib Mesylate Therapy in Chronic-Phase Chronic Myelogenous Leukemia (CML-CP) after IFN-α Failure and in Late CML-CP, Comparison with Historical Controls in another window
Journal Articles

Development of Varicella-Zoster Virus Infection in Patients with Chronic Myelogenous Leukemia Treated with Imatinib Mesylate

Gloria N. Mattiuzzi, Jorge E. Cortes, Moshe Talpaz, James Reuben, Mary Beth Rios, Jianjin Shan, Dimitrios Kontoyiannis, Francis J. Giles, Issam Raad, Srdan Verstovsek, Alessandra Ferrajoli, Hagop M. Kantarjian
Journal: Clinical Cancer Research
Clin Cancer Res (2003) 9 (3): 976–980.
Published: 01 March 2003
View article titled, Development of Varicella-Zoster Virus Infection in Patients with Chronic Myelogenous Leukemia Treated with Imatinib Mesylate
Open the PDF for Development of Varicella-Zoster Virus Infection in Patients with Chronic Myelogenous Leukemia Treated with Imatinib Mesylate in another window
Journal Articles

Effects of Signal Transduction Inhibitor 571 in Acute Myelogenous Leukemia Cells

Barbara Scappini, Francesco Onida, Hagop M. Kantarjian, Li Dong, Srdan Verstovsek, Michael J. Keating, Miloslav Beran
Journal: Clinical Cancer Research
Clin Cancer Res (2001) 7 (12): 3884–3893.
Published: 01 December 2001
View article titled, Effects of Signal Transduction Inhibitor 571 in Acute Myelogenous Leukemia Cells
Open the PDF for Effects of Signal Transduction Inhibitor 571 in Acute Myelogenous Leukemia Cells in another window